We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Feasibility Study on Biweekly Paclitaxel Treatment as Maintenance Chemotherapy in Advanced Müllerian Carcinoma.
- Authors
Minagawa, Yukihisa; Shimada, Muneaki; Itamochi, Hiroaki; Sato, Shinya; Sato, Seiya; Okada, Makoto; Kitada, Fuminori; Kigawa, Junzo
- Abstract
Aim: To evaluate the feasibility of biweekly paclitaxel treatment as maintenance chemotherapy for patients with advanced müllerian carcinoma. Methods: Thirty patients with stage III or IV ovarian, fallopian tube, and peritoneal cancers who underwent primary optimal surgery and standard 6 cycles of carboplatin/taxane-based chemotherapy and exhibited a complete clinical response were entered in this study. Paclitaxel 80 mg/m2 was administered biweekly for 12 cycles. Patients were evaluated monthly for treatment-related toxicity. Results: Four patients, including 3 disease progressions and 1 bone marrow suppression, came off the protocol therapy. Twenty-six (86.7%) patients received complete treatment. Although the major toxicity was neutropenia, most of those patients (27/30, 90.0%) did not experience grade 3 or 4 neutropenia. Twenty-four (80.0%) patients showed persistent grade 1 neuropathy and the remaining 6 (20.0%) did not as a result of prior therapy. However, none experienced neuropathy progression during or after the protocol therapy. Most (17/22, 77.3%) of the completely treated patients experienced a regression of symptoms during and after therapy. Conclusion: Biweekly paclitaxel therapy is well tolerated by patients with advanced müllerian carcinoma and is therefore acceptable as a candidate for maintenance chemotherapy in these patients. Copyright © 2012 S. Karger AG, Basel
- Subjects
PACLITAXEL; ANTINEOPLASTIC agents; DRUG therapy; NEUTROPENIA; FALLOPIAN tubes; CANCER in women
- Publication
Gynecologic & Obstetric Investigation, 2012, Vol 73, Issue 4, p272
- ISSN
0378-7346
- Publication type
Article
- DOI
10.1159/000332368